Aims and Scope of ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters is a peer-reviewed academic journal in the field of medicinal chemistry. Founded in 2009, this online journal is published monthly by the American Chemical Society. The Editor-in-Chief is Dennis C. Liotta (Emory University, Atlanta, Georgia, USA). Less
Key Metrics
CiteScore 

6.6
Eigenfactor 

0.01 - 0.05
Impact Factor 

< 5
SJR 

Q2Biochemistry

SNIP 

0.93
Recommended pre-submission checks
Powered by 

Topics Covered on ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | AMER CHEMICAL SOC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2010 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in ACS Medicinal Chemistry Letters ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in ACS Medicinal Chemistry Letters
Discovery of Pan-TEAD Inhibitors That Disrupt YAP-TEAD Interaction as a Potential Therapy for Gastric Cancers and Mutant KRAS and EGFR Lung Cancers
- 26 Feb 2026
- ACS Medicinal Chemistry Letters
<i>N</i> -Alkyl and <i>N</i> -Aryl Aminopyrazole Spirocarbamates: A Two-Pronged Lead Optimization Strategy to Identify Orally Bioavailable Plasma Kallikrein Inhibitors
- 24 Feb 2026
- ACS Medicinal Chemistry Letters
Multimodal Control of STAT6 Signaling through Small-Molecule Modulation and Targeted Degradation
- 23 Feb 2026
- ACS Medicinal Chemistry Letters
Modulation of Cancer Networks through Protein Degradation, DNA Repair Inhibition, and Quantitative Interactomics
- 23 Feb 2026
- ACS Medicinal Chemistry Letters
When Potency Is Not Enough: Aligning Modality, Exposure, and Biology
- 23 Feb 2026
- ACS Medicinal Chemistry Letters
<i>Bheka Thina</i> (“Look At Us”): The Emergence of an Integrated Drug Discovery Ecosystem in South Africa
- 22 Feb 2026
- ACS Medicinal Chemistry Letters
Discovery of Pan-TEAD Inhibitors That Disrupt YAP-TEAD Interaction as a Potential Therapy for Gastric Cancers and Mutant KRAS and EGFR Lung Cancers
- 26 Feb 2026
- ACS Medicinal Chemistry Letters
<i>N</i> -Alkyl and <i>N</i> -Aryl Aminopyrazole Spirocarbamates: A Two-Pronged Lead Optimization Strategy to Identify Orally Bioavailable Plasma Kallikrein Inhibitors
- 24 Feb 2026
- ACS Medicinal Chemistry Letters
Multimodal Control of STAT6 Signaling through Small-Molecule Modulation and Targeted Degradation
- 23 Feb 2026
- ACS Medicinal Chemistry Letters
Modulation of Cancer Networks through Protein Degradation, DNA Repair Inhibition, and Quantitative Interactomics
- 23 Feb 2026
- ACS Medicinal Chemistry Letters
When Potency Is Not Enough: Aligning Modality, Exposure, and Biology
- 23 Feb 2026
- ACS Medicinal Chemistry Letters
<i>Bheka Thina</i> (“Look At Us”): The Emergence of an Integrated Drug Discovery Ecosystem in South Africa
- 22 Feb 2026
- ACS Medicinal Chemistry Letters